Also known as: CSPC Pharmaceutical, CSPC Pharmaceutical Group Co., Ltd.
CSPC Pharmaceutical Group is a leading pharmaceutical group in China and is listed on the Hong Kong Stock Exchange. The company focuses on finished and bulk drugs with innovative medicines as its core development strategy.
Biopharma companies face a $275b patent cliff as licensing activity shifts toward China. China represented almost half of 2025 licensing activity and contributes about 30% of the global biotech pipeline.
Global pharmaceutical R&D deal values surged 49% to $86.7 billion in 2025 as companies concentrate investments in AI-powered drug discovery platforms, with average deal sizes reaching a record $1.16 billion despite fewer total partnerships.
CSPC Pharmaceutical Group has received approval from China's National Medical Products Administration to begin clinical trials for three drug candidates: a hemophilia A biosimilar, a long-acting pain medication, and an injection designated SYH9089.
Alphamab Oncology dosed the first patient in its Phase III trial of JSKN003, a biparatopic HER2-targeting antibody-drug conjugate, for HER2-positive advanced colorectal cancer on February 14, 2026.
Alphamab Oncology has dosed the first patient in a Phase III study of JSKN003, a biparatopic HER2-targeting ADC, for HER2-positive advanced colorectal cancer. The drug demonstrated a 68.8% response rate in earlier trials.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07397819 |
Intraperitoneal Injection of Liposomal Irinotecan as Monotherapy or in Combination With Recombinant Mutant Human Tumor Necrosis Factor or Bevacizumab for the Treatment of Malignant Ascites Following Failure of Prior Standard Therapy |
RECRUITING | PHASE1/PHASE2 |
| NCT06704685 |
A Randomized Controlled Trial on the Efficacy and Safety of Butylphthalide in Reducing Myocardial Infarction Size and Improving Outcomes in STEMI Patients After Primary PCI |
NOT_YET_RECRUITING | PHASE3 |
| NCT06220097 |
Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT05980416 |
Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2 |
TERMINATED | PHASE1 |
| NCT05603884 |
VCA Regimen Followed by D-MAG Regimen on the Treatment of Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) |
RECRUITING | PHASE2 |
| NCT04548440 |
Efficacy and Safety of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in BR-ESCC Patients |
COMPLETED | PHASE2 |
| NCT04101812 |
Pegylated Liposomal Doxorubicin, PD-1 in Treating Muscle Invasive Bladder Cancer |
UNKNOWN | PHASE2 |
